<SEC-DOCUMENT>0001193125-19-089230.txt : 20190328
<SEC-HEADER>0001193125-19-089230.hdr.sgml : 20190328
<ACCEPTANCE-DATETIME>20190328065233
ACCESSION NUMBER:		0001193125-19-089230
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190328
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190328
DATE AS OF CHANGE:		20190328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDNAX, INC.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				263667538
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		19709914

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d929503d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (date of earliest event reported): March&nbsp;28, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Florida</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-12111</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">26-3667538</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission File</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1301 Concord Terrace </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sunrise, Florida 33323 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) (zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code<U> (954) <FONT STYLE="white-space:nowrap">384-0175</FONT></U> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT
STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01&nbsp;&nbsp;&nbsp;&nbsp;Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;28, 2019, MEDNAX, Inc., a Florida corporation (the &#147;Company&#148;), issued a press release announcing that its Board of Directors has
nominated&nbsp;Carlos A. Migoya and Michael A. Rucker for election as directors at the Company&#146;s 2019 Annual Meeting of Shareholders alongside the current members of the Board, which would expand the size of the Board of Directors to 11
members. A copy of the Company&#146;s press release is attached as Exhibit 99.1 to this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d929503dex991.htm">Press Release of MEDNAX, Inc. dated March&nbsp;28, 2019. </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: March&nbsp;28, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Stephen D. Farber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen D. Farber</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d929503dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g929503image000145.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR MORE INFORMATION: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles Lynch </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Strategy and Investor Relations
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">954-384-0175</FONT></FONT> ext. 5692 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>charles_lynch@mednax.com </U></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>FOR IMMEDIATE RELEASE
</U></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX Announces Board of Directors Nominees </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Carlos A. Migoya and Michael A. Rucker Nominated for Election to the </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company&#146;s Board of Directors </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FORT
LAUDERDALE, Fla</B>., March&nbsp;28, 2019 &#150; MEDNAX, Inc. (NYSE: MD), the national health solutions partner specializing in neonatology, anesthesiology, radiology, maternal-fetal medicine, other pediatric services, and management services, today
announced the nomination of Carlos A. Migoya and Michael A. Rucker to stand for election to the Company&#146;s Board of Directors at its Annual Meeting of Shareholders on May&nbsp;16, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously announced, MEDNAX&#146;s Board and its Nominating and Corporate Governance Committee initiated a process, with the support of the
nationally-recognized executive search firm Spencer Stuart, to evaluate the Board&#146;s composition and identify additional director candidates to help drive MEDNAX&#146;s strategy. As a result of that process, the Board, following the
recommendation of its Nominating and Corporate Governance Committee, nominated Carlos A. Migoya and Michael A. Rucker to stand for election to the Company&#146;s Board of Directors, alongside the current members of the Board, which would expand the
size of the Board of Directors to 11 members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to announce the nominations of Carlos and Michael to stand for election by our
shareholders to our Board,&#148; said Cesar L. Alvarez, Chairman of the Board. &#147;As we work to execute on our strategy to drive long-term growth and deliver value to our shareholders, we are committed to maintaining a Board that provides robust
oversight and has the right skills to support and advise MEDNAX. Carlos and Michael will bring to our Board extensive experience as healthcare and business leaders at a variety of enterprises, and their expertise will be critical as we implement our
strategy over the coming years.&#148; </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Carlos A. Migoya </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since 2011, Carlos A. Migoya has served as President and Chief Executive Officer of Jackson Health System, the public health system for Miami-Dade County,
which includes Jackson Memorial Hospital, Jackson South Medical Center, Jackson North Medical Center, Holtz Children&#146;s Hospital, Jackson Rehabilitation Hospital, Jackson Behavioral Health Hospital, urgent care centers, multiple primary care and
specialty care centers, two long-term care nursing facilities and a team of corrections health services clinics, and generated over $1.8&nbsp;billion in revenue in 2016.&nbsp;Mr.&nbsp;Migoya led the transformation of Jackson Health System from a
large budget deficit in the year before his tenure, to budget surpluses in each subsequent year.&nbsp;Prior to joining Jackson Health System, Mr.&nbsp;Migoya served as City Manager for the City of Miami from 2010 to 2011, a position he held in a pro
bono capacity, while eliminating a $115&nbsp;million budget deficit. Prior to serving as City Manager, Mr.&nbsp;Migoya worked for Wells Fargo&nbsp;&amp; Company and its predecessors, including Wachovia Corporation and First Union Corporation, for
more than 25 years, retiring as Regional President, North Carolina and Chief Executive Officer, Atlantic Region.&nbsp;Mr.&nbsp;Migoya served as a member of the board of directors of AutoNation, Inc. from 2006-2015.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Michael A. Rucker </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since 2017, Michael A. Rucker has
served as Chief Executive Officer, and since 2016 as a member of the Board of Directors, of Ivy Rehab Network, Inc., one of the largest networks of physical therapy clinics in the United States.&nbsp;Prior to joining Ivy&nbsp;Rehab, Mr.&nbsp;Rucker
served from 2010 to 2017 as Executive Vice President and Chief Operating Officer of Surgical Care Affiliates, Inc., at the time a publicly traded operator of one of the&nbsp;nation&#146;s&nbsp;largest networks of surgical&nbsp;facilities,
until&nbsp;its acquisition by UnitedHealth Group.&nbsp;Mr.&nbsp;Rucker has also held executive roles in various healthcare companies, including DaVita, Inc., where he served as Division Vice&nbsp;President from&nbsp;2005 to 2008 after DaVita
acquired Gambro Healthcare, where Mr.&nbsp;Rucker had served in various&nbsp;general management and business development&nbsp;capacities since&nbsp;1997.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Additional Information and Where You Can Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. (the &#147;Company&#148;), its directors and certain of its executive officers may be deemed to be participants in a solicitation of proxies from
the Company&#146;s shareholders at its 2019 Annual Meeting of Shareholders in connection with the director nominations disclosed above. Information regarding the Company&#146;s directors and executive officers and their respective interests in the
Company, by security holdings or otherwise, will be set forth in the Company&#146;s Definitive Proxy Statement for its 2019 Annual Meeting of Shareholders, to be filed with the Securities and Exchange Commission (the &#147;SEC&#148;), and reports
filed by the Company and ownership forms filed by its directors and executive officers with the SEC. The Company will furnish its Definitive Proxy Statement for its 2019 Annual Meeting of Shareholders to shareholders entitled to vote at the meeting
and will file a copy with the SEC. The Company urges its shareholders to carefully read the Definitive Proxy Statement for its 2019 Annual Meeting of Shareholders, and any other relevant documents filed by the Company with the SEC, when available
because they will contain important information. Shareholders will be able to receive the proxy statement and other relevant documents free of charge at the SEC&#146;s website at www.sec.gov or at <U>www.mednax.com</U>. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT MEDNAX </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. is a national health solutions partner based in Sunrise, Fla. comprised of the nation&#146;s leading providers of physician services. Physicians
and advanced practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives, clinical research and telemedicine to enhance patient
outcomes and provide high-quality, cost-effective care. The Company was founded in 1979, and today, through its affiliated professional corporations, MEDNAX provides services through a network of more than 4,200 physicians in all 50 states and
Puerto Rico. In addition to its national physician network, MEDNAX provides services to healthcare facilities and physicians in over 40 states through two complementary businesses, consisting of a revenue cycle management company and a consulting
services company. Additional information is available at <U>www.mednax.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating
to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These
statements are often characterized by terminology such as &#147;believe,&#148; &#147;hope,&#148; &#147;may,&#148; &#147;anticipate,&#148; &#147;should,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;will,&#148; &#147;expect,&#148;
&#147;estimate,&#148; &#147;project,&#148; &#147;positioned,&#148; &#147;strategy&#148; and similar expressions, and are based on assumptions and assessments made by MEDNAX&#146;s management in light of their experience and their perception of
historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and&nbsp;MEDNAX undertakes no duty to update
or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause
actual results, developments, and business decisions to differ materially from forward-looking statements are described in MEDNAX&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and its Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q,</FONT> including the sections entitled &#147;Risk Factors&#148;, as well MEDNAX&#146;s current reports on Form <FONT STYLE="white-space:nowrap">8-K,filed</FONT> with the&nbsp;Securities and Exchange Commission,
and include the effects of economic conditions on MEDNAX&#146;s business; the effects of the Affordable Care Act and potential changes thereto or a repeal thereof; MEDNAX&#146;s relationships with government-sponsored or funded healthcare programs,
including&nbsp;Medicare&nbsp;and&nbsp;Medicaid, and with managed care organizations and commercial health insurance payors; MEDNAX&#146;s ability to consummate the proposed disposition of MedData; the results of the election of directors at
MEDNAX&#146;s 2019 Annual Meeting of Shareholders; the effects of share repurchases; and the effects of MEDNAX&#146;s shared services and operational initiatives. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g929503image000145.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g929503image000145.jpg
M_]C_X  02D9)1@ ! 0$ W0#=  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M(QX3\36^L&U^UB!77RO,V9W*5ZX/KZ5Z$[\KY=SAA;F7-L>H?\* B_Z&)_\
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MBW"37$D@*.>,@ .>I]A3=<\-W&J:EK$JF6(O!"+<B0K'*R[LJR@\CH.>F>*
M.GT^[2^L;>[B#*D\:RJ&Z@,,C/YU8JKI;N^GP-);&T?8 83C]V0.G'8=JM4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1112Z@%%%%, HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
